-
Genomic Characterization of Patients in A Phase 2 Study of Zanubrutinib in BTK Inhibitor–Intolerant Patients With Relapsed/Refractory B-Cell Malignancies
American Society of Hematology, 2022
-
Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient or Inpatient Treatment in The Community/Nonuniversity Setting in Patients (Pts) With Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL
American Society of Hematology, 2022
-
Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared With Ibrutinib For Treatment of R/R Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results From Final Analysis of ALPINE Randomized Phase 3 Study
American Society of Hematology, 2022
-
Improvements in Health-related Quality of Life and Symptoms in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Final Results From the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine
Clinical Lymphoma, Myeloma and Leukemia, 2021
-
Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) For Advanced Stage Classic Hodgkin Lymphoma: Preliminary Safety Results From The Single-Arm Phase 2 Study (SGN35-027 Part B)
American Society of Hematology, 2021
-
Debulking Before Initiation of Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Results From A Phase 3b Study
American Society of Hematology, 2021
-
Detection of Cancer Signal For Over 50 AJCC Cancer Types With A Multi-Cancer Early-Detection Test
American Society of Clinical Oncology, 2021
-
Performance of a targeted Methylation-Based Multi-Cancer Early Detection Test By Race/Ethnicity
American Society of Clinical Oncology, 2021
-
Daratumumab (DARA) Maintenance Therapy Following DARA + Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): End-of-Study Analysis of LYRA
American Society of Clinical Oncology, 2021
-
CheckMate 8KX: Phase 1/2 Multitumor Preliminary Analyses of A Subcutaneous Formulation of Nivolumab (± rHuPH20)
American Society of Clinical Oncology, 2021
-
Outreach: Preliminary Safety and Efficacy Results From A Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) in the Nonuniversity setting
American Society of Clinical Oncology, 2021
-
Preliminary Results of The Phase 2 Study of Zanubrutinib in Patients With Previously Treated B-cell Malignancies Intolerant to Ibrutinib and/or Acalabrutinib
American Society of Clinical Oncology, 2021
-
Phase 2, Multicenter GIBB Study of Obinutuzumab Plus Bendamustine in Previously Untreated Patients With Chronic Lymphocytic Leukemia
Leukemia & Lymphoma, 2021
-
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib
Clinical Lymphoma, Myeloma & Leukemia, 2020
-
Phase 2 Study of Zanubrutinib in Patients With Previously Treated B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib
American Society of Hematology, 2020
-
Debulking Regimens Prior To Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Interim Results from a Phase 3b Study
American Society of Hematology, 2020
-
In-Class Transition From Parenteral Bortezomib to Oral Ixazomib Proteasome Inhibitor Therapy Increases the Feasibility of Long-Term Proteasome Inhibitor Treatment and Benefit for Newly Diagnosed Multiple Myeloma Patients in an Outpatient Setting: Updated Real-World Results from the Community-Based US MM-6 Study
American Society of Hematology, 2020
-
Long-Term Proteasome Inhibition in Multiple Myeloma Following an in-Class Transition from Bortezomib-Based Induction to All-Oral Ixazomib Lenalidomide- Dexamethasone in The US MM-6 Community-Based Study: Subgroup Analyses of Real-World Data in Patients Aged <75 and ≥75 Years
The Society of Hematologic Oncology, 2020
-
Phase 3b Study to Evaluate Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients With Chronic Lymphocytic Leukemia
The Society of Hematologic Oncology, 2020
-
Long-Term Proteasome Inhibition in Multiple Myeloma (Mm) Following an In- Class Transition From Bortezomib (Btz) To Ixazomib (Ixa): Updated Real-World (Rw) Data From The Us Mm-6 Community-Based Study
European Hematology Association, 2020
-
Long-Term Proteasome Inhibition in US Community Multiple Myeloma (MM) Patients (pts) Following In-Class Transition (iCT) from Parenteral Bortezomib (V) to Oral ixazomib (I): Updated Real-World (RW) Data from US MM-6
American Society of Clinical Oncology, 2020
-
Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study
American Society of Hematology, 2019
-
Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-free Survival (PFS) Following DARA plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update LYRA Study
American Society of Hematology, 2019
-
Final Results from the Multicenter, Open-Label, Phase II GIBB Study of Obinutuzumab + Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia
American Society of Hematology, 2019
-
Improvements in Health-Related Quality of Life and Symptoms in Patients with Previously Untreated Chronic Lymphocytic Leukemia: Final Results from The Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine
American Society of Hematology, 2019
-
Phase 1/2 Trial of Acalabrutinib Plus Pembrolizumab in R/R Diffuse Large B-Cell Lymphoma
International Conference on Malignant Lymphoma, 2019
-
Phase 1/2 Trial of Acalabrutinib Plus Pembrolizumab (Pem) in Relapsed/Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL)
American Society of Clinical Oncology, 2019
-
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
The New England Journal of Medicine, 2019
-
Pembrolizumab Plus Lenalidomide and Dexamethasone for Patients With Treatment-Naive Multiple Myeloma (KEYNOTE-185): A Randomised, Open-Label, Phase 3 Trial
The Lancet. Haematology, 2019
-
Daratumumab, Bortezomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed and Relapsed Multiple Myeloma: LYRA Study
British Journal of Haematology, 2019
-
Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma
The New England Journal of Medicine, 2019
-
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
The New England Journal of Medicine, 2019
-
A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) With Multiple Myeloma (MM)
American Society of Hematology, 2018
-
Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of A Randomized Clinical Trial (CASSINI)
American Society of Hematology, 2018
-
A Phase 3 Randomized Study of Pembrolizumab (Pembro) Plus Lenalidomide (Len) and Low-Dose Dexamethasone (Rd) Versus Rd for Newly Diagnosed and Treatment-Naive Multiple Myeloma (MM): K. N-185
American Society of Clinical Oncology, 2018
-
Results of an Interim Safety Analysis of a Phase 2 Study of Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Previously Untreated and Relapsed Patients With Multiple Myeloma
American Society of Hematology, 2017
-
Results of A Phase II Multicenter Study of Obinutuzumab Plus Bendamustine in Pts With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
American Society of Clinical Oncology, 2017
-
Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp as Frontline Therapy in Patients With High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL)
American Society of Hematology, 2016
-
A Phase Ib/II Study of Cancer Stemness Inhibitor Napabucasin (BB608) Combined With Weekly Paclitaxel in Platinum-Resistant Ovarian Cancer
American Society of Clinical Oncology, 2016
-
Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients With High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL)
American Society of Hematology, 2015